40Over40: A New Campaign To Tackle Low Awareness Of Erectile Dysfunction And Its Health Implications In Younger Men A new survey of 1,000 men aged over 40, commissioned by Eli Lilly and Company Limited (Lilly UK) as part of a new erectile dysfunction awareness campaign, 40over40, reveals that just over 10% of men in their early 40s are aware that ED strikes regularly in the fourth decade even though evidence suggests that 40% of men aged 40 or over have some form of ED.
Source: www.medicalnewstoday.comFibromyalgia Stumps Doctors Physicians are often slow to diagnose fibromyalgia, and multiple reasons may account for the delay, new data suggest. The results, from a survey that polled 1,622 physicians in eight countries as well as 800 patients with a confirmed diagnosis of fibromyalgia, also show that the condition has significant economic consequences. In short, fibromyalgia can lead to job absenteeism, job dismissal, and loss of income.
Source: www.medicalnewstoday.comParadox Discovered About General Anesthesia: It Can Increase Post-Surgical Pain The general anesthesia that puts patients into unconscious sleep so they do not feel surgical pain can increase the discomfort they feel once they wake up, say researchers from Georgetown University Medical Center. They say their findings, the first to scientifically explain what has been anecdotally observed in the clinic, may lead to wider use of the few anesthetics that don't have this side effect, or to the development of new ones.
Source: www.medicalnewstoday.comHow Pain Scores In Babies Methods commonly used by doctors to assess pain in infants may be underestimating the amount of pain they feel, according to a study by UCL (University College London) researchers. Clinical pain scoring methods, which look for a range of behavioural and physiological responses, such as body movements and changes in blood pressure, may need to be revised to focus on the strongest indicators of pain.
Source: www.medicalnewstoday.comAlexza Pharmaceuticals To Present AZ-104 Phase 2a Clinical Data At The American Headache Society Annual Scientific Meeting Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it will present results of its Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) for the treatment of migraine headache at the 50th Annual Scientific Meeting of the American Headache Society, which being held at the Marriott Boston Copley Place in Boston, MA.
Source: www.medicalnewstoday.comLabels: No Prescription, Online Pharmacy
# posted by Network @ 6:00 PM
